Int J Med Sci 2020; 17(3):302-309. doi:10.7150/ijms.39342 This issue Cite

Research Paper

Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events

Sayoko Kinoshita1, Kouichi Hosomi2, Satoshi Yokoyama2, Mitsutaka Takada2✉

1. Ebisu Pharmacy, 2-7-24, Motomachi, Naniwa-ku, Osaka-shi, Osaka, Japan
2. Division of Clinical Drug Informatics, School of Pharmacy, Kindai University, 3-4-1, Kowakae, Higashi-osaka, Osaka, Japan

Citation:
Kinoshita S, Hosomi K, Yokoyama S, Takada M. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events. Int J Med Sci 2020; 17(3):302-309. doi:10.7150/ijms.39342. https://www.medsci.org/v17p0302.htm
Other styles

File import instruction

Abstract

Background: The association between metformin and amiodarone-induced adverse events was examined using spontaneous adverse event database. Additionally, the association between other antidiabetic drugs and amiodarone-induced adverse events were also examined.

Methods: A total of 6,153,696 reports from the first quarter of 2004 through the fourth quarter of 2015 were downloaded from the US Food and Drug Administration adverse event reporting system. Reporting odds ratio (ROR) and information component (IC) were used to detect associations between antidiabetic drugs and amiodarone-associated adverse events. Additionally, subset data analysis was performed to investigate whether the use of antidiabetic drugs further increased or decreased the risk of adverse events in patients receiving amiodarone therapy. Next, the RORs were adjusted for coadministered antidiabetic drugs using logistic regression analysis.

Results: By whole dataset analysis, significant inverse associations were found between metformin and interstitial lung disease (ROR 0.84, 95% confidence interval [CI] 0.79-0.90; IC -0.24, 95% CI -0.33 to -0.15). In the subset data analysis, metformin (ROR 0.62, 95%CI 0.43-0.89; IC -0.63, 95%CI -1.14 to -0.11), sulfonylureas (ROR 0.53, 95%CI 0.32-0.85; IC -0.85, 95%CI -1.53 to -0.17), and dipeptidyl peptidase-4 (DPP-4) inhibitors (ROR 0.25, 95%CI 0.08-0.78; IC -1.66, 95%CI -3.08 to -0.23) were inversely associated with hyperthyroidism. Additionally, metformin (ROR 0.43, 95%CI 0.33-0.57; IC -1.09, 95%CI -1.49 to -0.69), sulfonylureas (ROR 0.64, 95%CI 0.48-0.86; IC -0.59, 95%CI -1.00 to -0.17), and DPP-4 inhibitors (ROR 0.47, 95%CI 0.27-0.81; IC -0.99, 95%CI -1.76 to -0.22) were inversely associated with interstitial lung disease. In the logistic regression analyses, DPP-4 inhibitors (adjusted ROR 0.32, 95% CI 0.10-1.00) and metformin (adjusted ROR 0.46, 95% CI 0.34-0.62) were inversely associated with amiodarone-associated hyperthyroidism and interstitial lung disease, respectively.

Conclusion: Metformin is a candidate drug to reduce the risk of amiodarone-induced hyperthyroidism and interstitial lung disease.

Keywords: adverse event, amiodarone, antidiabetic drug, Food and Drug Administration adverse event reporting system, metformin


Citation styles

APA
Kinoshita, S., Hosomi, K., Yokoyama, S., Takada, M. (2020). Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events. International Journal of Medical Sciences, 17(3), 302-309. https://doi.org/10.7150/ijms.39342.

ACS
Kinoshita, S.; Hosomi, K.; Yokoyama, S.; Takada, M. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events. Int. J. Med. Sci. 2020, 17 (3), 302-309. DOI: 10.7150/ijms.39342.

NLM
Kinoshita S, Hosomi K, Yokoyama S, Takada M. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events. Int J Med Sci 2020; 17(3):302-309. doi:10.7150/ijms.39342. https://www.medsci.org/v17p0302.htm

CSE
Kinoshita S, Hosomi K, Yokoyama S, Takada M. 2020. Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events. Int J Med Sci. 17(3):302-309.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image